Monashee Scales Back Structure: GPCR Bet Reassessed
A major hedge fund slashed its stake in Structure Therapeutics, prompting questions about the future path for GPCR-fo...
Get paid for your opinions! Explore websites that reward you for sharing your thoughts and start earning today.
18,862 articlesA major hedge fund slashed its stake in Structure Therapeutics, prompting questions about the future path for GPCR-fo...
Target stock has captured attention as it tries to outpace rivals like Amazon, Walmart, and Costco. This guide breaks...
MercadoLibre faced a sharp price move after a quarter that showed strong top-line momentum but weaker profitability. ...
A proposed seven-year sell-off rule could alter the economics of build-to-rent projects. This article breaks down wha...
A company with a massive market cap and years of losses is making waves in investing circles. This piece breaks down ...
When Paramount beat Netflix in the bid for Warner Bros. Discovery’s assets, headlines screamed victory. This piece di...
Analysts often set price targets to frame potential moves for AI stocks. This article breaks down how those targets a...
A Monday rebound lifted the Nasdaq and S&P as chipmakers regain momentum after Friday's sell-off. This guide breaks d...
A fictional scenario explores how an iran-linked group that hacked a high-profile email might hijack drone footage an...
New Federal Reserve data shows the average retirement stash sits around $333,940, but the median remains far lower, u...
Markets recalibrate after a run by the Magnificent Seven, pushing many to rethink concentration. Three ETFs—RSP, SCHV...
Choosing between broad health care exposure and a concentrated pharma tilt can shape risk, returns, and your overall ...